The results of this research, published June 1, 2011 in the journal PLoS ONE, have shown that RNAi, which is already the subject of more than a dozen clinical trials to target illnesses ranging from cancer to asthma, functions normally in space flight and could be used as a viable option to treat and control muscle degradation in spaceflight. Their discovery will not only be of interest to astronauts but will also help people who suffer from muscle wasting caused by illness and old age